更昔洛韦在D+/R+肾移植术后预防CMV感染的疗效观察  

Prophylactic Treatment of Ganciclovir to Prevent Cytomegalovirus Infection in D+/R+ Renal Allograft Recipients

作　　者：曲楠[1] 董金凯[1] 赵立[1] 麦海星[1] 陈彪[1] 陈立军[1] 

机构地区：[1]军事医学科学院附属医院泌尿外科,北京100071

出　　处：《现代生物医学进展》2016年第5期891-893,897,共4页Progress in Modern Biomedicine

摘　　要：目的:观察D+/R+肾移植术后人群应用更昔洛韦预防巨细胞病毒感染的疗效与安全性。方法:我院2003年5月至2011年11月期间D+/R+同种异体肾移植患者93例,肾移植术后预防性应用更昔洛韦,对移植后1年内巨细胞病毒的感染率、感染发生的时间及有症状的CMV发病率进行以及用药后不良事件进行分析。结果:在D+/R+肾移植人群中预防性使用更昔洛韦后的感染率为28%,有症状的CMV发病率4.3%,病毒血症的平均感染时间为231.3 d,严重不良事件发生率为45.1%。结论:在D+/R+肾移植术后患者中预防性更昔洛韦能够预防CMV感染并且延长CMV初次感染时间,使D+/R+肾移植患者获益。Objective： To assess the efficacy and tolerability of ganciclovir to prevent cytomegalovirus（CMV）infection after renal transplantation. Methods： 93 D＋/R＋ renal allograft recipients were given Prophylactic treatment of ganciclovir, and the incidence of CMV infection and the time of infection and adverse event in 1year was observed. Results： In D＋/R＋ renal allograft recipients who were received ganciclovir prophylaxis, the incidence of CMV infection were 28 %, and the time to first viremia was 231.3 d. The incidence of serious adverse events was 45.1 %. Conclusions： Ganciclovir prophylaxis significantly reduces CMV infection in D＋/R＋ renal allograft recipients. However, it needs further studies in RCT.

关 键 词：肾移植 巨细胞病毒 更昔洛韦 预防性用药 

分 类 号：R617[医药卫生—外科学] R692[医药卫生—临床医学]